Luis De La Cruz Merino - Publications

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2025

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.

Journal: ESMO open

Published: July 08, 2025

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 27, 2025

Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).

Journal: Cancer

Published: March 12, 2025

Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.

Journal: Annals of surgical oncology

Published: July 18, 2024

SEOM-GEM clinical guidelines for cutaneous melanoma (2023).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 22, 2024

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 07, 2024

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

Journal: The Lancet. Oncology

Published: July 17, 2023

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 29, 2022

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.

Journal: Breast (Edinburgh, Scotland)

Published: July 21, 2022

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: July 13, 2022

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

Journal: The Lancet. Oncology

Published: March 29, 2022